<DOC>
	<DOCNO>NCT02340221</DOCNO>
	<brief_summary>This international , multicenter , randomize , double-blinded , placebo-controlled study design compare efficacy safety taselisib + fulvestrant placebo + fulvestrant postmenopausal woman estrogen receptor ( ER ) -positive , human epidermal growth factor receptor-2 ( HER2 ) -negative , PIK3CA-mutant , unresectable , locally advanced metastatic breast cancer recurrence progression aromatase inhibitor ( AI ) therapy . There 2:1 randomization taselisib arm versus placebo arm . Enrollment enrich patient PIK3CA mutant tumor via central test . The anticipated duration study approximately 3.5 year .</brief_summary>
	<brief_title>SANDPIPER Study : A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced Metastatic Breast Cancer Who Have Disease Recurrence Progression During After Aromatase Inhibitor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman histologically cytologically confirm locally advanced metastatic estrogenreceptor positive ( ER+ ) breast cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Endocrine therapy ( e.g. , fulvestrant ) recommend treatment cytotoxic chemotherapy indicate time entry study Radiologic/objective evidence recurrence progression recent systemic therapy breast cancer Recurrence progression aromatase inhibitor Evaluable measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Consent provide tumor tissue ( block minimum 20 slide ) recent tumor tissue PIK3CAmutation testing ; valid cobasÂ® PIK3CA mutation result central testing require Adequate hematologic endorgan function within 28 day prior treatment initiation HER2positive disease local laboratory testing ( immunohistochemistry [ IHC ] 3+ stain situ hybridization positive ) Prior treatment fulvestrant Prior treatment PI3K inhibitor , mTOR inhibitor ( e.g . everolimus ) , AKT inhibitor Prior anticancer therapy within 2 week prior Day 1 Cycle 1 Prior radiation therapy within 2 week prior Day 1 Cycle 1 All acute treatmentrelated toxicity must resolve Grade &lt; /= 1 deem stable Investigator Prior treatment &gt; 1 cytotoxic chemotherapy regimen metastatic breast cancer Concurrent hormone replacement therapy Known untreated active central nervous system ( CNS ) metastases Type 1 Type 2 diabetes mellitus require antihyperglycemic medication History inflammatory bowel disease active bowel inflammation Clinically significant cardiac pulmonary dysfunction Clinically significant history liver disease , include cirrhosis , current alcohol abuse , current know active infection HIV , hepatitis B C virus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>